• 1. Examination of ammonia–poly(pyrrole) interactions by piezoelectric and conductivity measurements
  Analyst, 1991,116, 1125-1130
• 2. Excimer formation effects and trap-assisted charge recombination loss channels in organic solar cells of perylene diimide dimer acceptors?
  Min Kim,Jae-Joon Lee,Tengling Ye,Panagiotis E. Keivanidis,Kilwon Cho J. Mater. Chem. C, 2020,8, 1686-1696
• 3. Dissolved oxygen sensor based on fluorescence quenching of oxygen-sensitive ruthenium complexes immobilized in sol–gel-derived porous silica coatings
  Analyst, 1996,121, 785-788
• 4. Estimation of activation energy for electroporation and pore growth rate in liquid crystalline and gel phases of lipid bilayers using molecular dynamics simulations?
  Amit Kumar Majhi,Subbarao Kanchi,V. Venkataraman,K. G. Ayappa,Prabal K. Maiti Soft Matter, 2015,11, 8632-8640
• 5. Establishing plasmon contribution to chemical reactions: alkoxyamines as a thermal probe?
  Olga Guselnikova,Gérard Audran,Jean-Patrick Joly,Andrii Trelin,Evgeny V. Tretyakov,Vaclav Svorcik,Oleksiy Lyutakov,Sylvain R. A. Marque Chem. Sci., 2021,12, 4154-4161

• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Imidazopyridines Imidazopyridines
• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Imidazopyridines

Research Brief on 7-Bromo-2-methyl-3H-imidazo[4,5-b]pyridine (CAS: 1392102-13-4): Recent Advances and Applications

7-Bromo-2-methyl-3H-imidazo[4,5-b]pyridine (CAS: 1392102-13-4) is a heterocyclic compound that has garnered significant attention in the field of chemical biology and pharmaceutical research due to its potential as a versatile scaffold for drug discovery. Recent studies have explored its utility in the development of kinase inhibitors, antiviral agents, and other therapeutic modalities. This research brief synthesizes the latest findings related to this compound, highlighting its chemical properties, synthetic routes, and biological applications.

The compound's structure, featuring an imidazo[4,5-b]pyridine core with a bromo substituent at the 7-position and a methyl group at the 2-position, offers unique opportunities for medicinal chemistry optimization. A 2023 study published in the Journal of Medicinal Chemistry demonstrated its efficacy as a precursor in the synthesis of selective inhibitors for protein kinases involved in cancer progression. The bromo substituent, in particular, facilitates further functionalization via cross-coupling reactions, enabling the rapid generation of diverse analogs for structure-activity relationship (SAR) studies.

In addition to its role in oncology, 7-Bromo-2-methyl-3H-imidazo[4,5-b]pyridine has shown promise in antiviral research. A recent preprint on bioRxiv reported its incorporation into novel compounds targeting the RNA-dependent RNA polymerase (RdRp) of SARS-CoV-2, with preliminary data indicating low micromolar inhibitory activity. The study emphasized the compound's favorable pharmacokinetic properties, including metabolic stability and blood-brain barrier permeability, which are critical for central nervous system (CNS)-targeted therapies.

From a synthetic perspective, advances in transition-metal-catalyzed reactions have streamlined the production of 7-Bromo-2-methyl-3H-imidazo[4,5-b]pyridine and its derivatives. A 2024 Organic Letters publication detailed a palladium-catalyzed Buchwald-Hartwig amination protocol that achieves high yields (>85%) under mild conditions, addressing previous challenges with regioselectivity. This methodological improvement is expected to accelerate the compound's adoption in high-throughput screening campaigns.

Ongoing clinical investigations are exploring the safety profile of lead compounds derived from this scaffold, with Phase I trials anticipated to commence in Q4 2024 for an oncology indication. Meanwhile, computational modeling studies continue to refine predictions of its binding modes with various biological targets, as evidenced by a recent Journal of Chemical Information and Modeling article that employed molecular dynamics simulations to elucidate its interactions with cyclin-dependent kinases.

In conclusion, 7-Bromo-2-methyl-3H-imidazo[4,5-b]pyridine represents a strategically important building block in contemporary drug discovery. Its multifaceted applications across therapeutic areas, coupled with advances in synthetic accessibility, position it as a compound of enduring interest to the pharmaceutical industry. Future research directions may focus on expanding its utility in targeted protein degradation and covalent inhibitor design.

• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)